Integrating Biomarkers for Underlying Alzheimer’s Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers
Restricted accessResearch articleFirst published online January 12, 2016
Integrating Biomarkers for Underlying Alzheimer’s Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers
Recent criteria allow biomarkers to provide evidence of Alzheimer’s disease (AD) pathophysiology. How they should be implemented in daily practice remains unclear, especially in mild cognitive impairment (MCI) patients.
Objective:
We evaluated how a clinical decision support system such as the PredictAD tool can aid clinicians to integrate biomarker evidence to support AD diagnosis.
Methods:
With available data on demographics, cerebrospinal fluid (CSF), and MRI, we trained the PredictAD tool on a reference population of 246 controls and 491 AD patients. We then applied the identified algorithm to 211 MCI patients. For comparison, we also classified patients based on individual biomarkers (MRI; CSF) and the NIA-AA criteria. Progression to dementia was used as outcome measure.
Results:
After a median follow up of 3 years, 72 (34%) MCI patients remained stable and 139 (66%) progressed to AD. The PredictAD tool assigned a likelihood of underlying AD to each patient (AUC 0.82). Excluding patients with missing data resulted in an AUC of 0.87. According to the NIA-AA criteria, half of the MCI patients had uninformative biomarkers, precluding an assignment of AD likelihood. A minority (41%) was assigned to high or low AD likelihood with good predictive value. The individual biomarkers showed best value for CSF total tau (AUC 0.86).
Conclusion:
The ability of the PredictAD tool to identify AD pathophysiology was comparable to individual biomarkers. The PredictAD tool has the advantage that it assigns likelihood to all patients, regardless of missing or conflicting data, allowing clinicians to integrate biomarker data in daily practice.
PetersenRC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med256, 183–194.
3.
VosSJ, XiongC, VisserPJ, JasielecMS, HassenstabJ, GrantEA, CairnsNJ, MorrisJC, HoltzmanDM, FaganAM (2013) Preclinical Alzheimer’s disease and its outcome: A longitudinal cohort study. Lancet Neurol12, 957–965.
4.
AlbertMS, DekoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
5.
DuboisB, FeldmanHH, JacovaC, DekoskyST, Barberger-GateauP, CummingsJ, DelacourteA, GalaskoD, GauthierS, JichaG, MeguroK, O’brienJ, PasquierF, RobertP, RossorM, SallowayS, SternY, VisserPJ, ScheltensP (2007) Research criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol6, 734–746.
6.
HampelH, FrankR, BroichK, TeipelSJ, KatzRG, HardyJ, HerholzK, BokdeAL, JessenF, HoesslerYC, SanhaiWR, ZetterbergH, WoodcockJ, BlennowK (2010) Biomarkers for Alzheimer’s disease: Academic, industry and regulatory perspectives. Nat Rev Drug Discov9, 560–574.
7.
BoccardiM, GanzolaR, BocchettaM, PievaniM, RedolfiA, BartzokisG, CamicioliR, CsernanskyJG, De LeonMJ, de Toledo-MorrellL, KillianyRJ, LehericyS, PantelJ, PruessnerJC, SoininenH, WatsonC, DuchesneS, JackCRJr, FrisoniGB (2011) Survey of protocols for the manual segmentation of the hippocampus: Preparatory steps towards a joint EADC-ADNI harmonized protocol. J Alzheimers Dis26(Suppl 3), 61–75.
8.
SperlingR, JohnsonK (2013) Biomarkers of Alzheimer disease: Current and future applications to diagnostic criteria. Continuum (Minneap Minn)19, 325–338.
9.
BlennowK, DuboisB, FaganAM, LewczukP, De LeonMJ, HampelH (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease. Alzheimers Dement11, 58–69.
10.
LiuY, MattilaJ, RuizMA, PaajanenT, KoikkalainenJ, van GilsGM, HerukkaSK, WaldemarG, LotjonenJ, SoininenH (2013) Predicting AD conversion: Comparison between prodromal AD guidelines and computer assisted PredictAD tool. PLoS One8, e55246.
11.
AntilaK, LotjonenJ, ThurfjellL, LaineJ, MassiminiM, RueckertD, ZubarevRA, OresicM, van GilsGM, MattilaJ, HviidSA, WaldemarG, SoininenH (2013) The PredictAD project: Development of novel biomarkers and analysis software for early diagnosis of the Alzheimer’s disease. Interface Focus3, 20120072.
12.
MattilaJ, KoikkalainenJ, VirkkiA, van GilsGM, LotjonenJ (2012) Design and application of a generic clinical decision support system for multiscale data. IEEE Trans Biomed Eng59, 234–240.
13.
SimonsenAH, MattilaJ, HejlAM, FrederiksenKS, HerukkaSK, HallikainenM, van GilsGM, LotjonenJ, SoininenH, WaldemarG (2012) Application of the PredictAD software tool to predict progression in patients with mild cognitive impairment. Dement Geriatr Cogn Disord34, 344–350.
14.
MattilaJ, SoininenH, KoikkalainenJ, RueckertD, WolzR, WaldemarG, LotjonenJ (2012) Optimizing the diagnosis of early Alzheimer’s disease in mild cognitive impairment subjects. J Alzheimers Dis32, 969–979.
15.
SoininenH, MattilaJ, KoikkalainenJ, van GilsGM, HviidSA, WaldemarG, RueckertD, ThurfjellL, LotjonenJ (2012) Software tool for improved prediction of Alzheimer’s disease. Neurodegener Dis10, 149–152.
16.
MattilaJ, KoikkalainenJ, VirkkiA, SimonsenA, van GilsGM, WaldemarG, SoininenH, LotjonenJ (2011) A disease state fingerprint for evaluation of Alzheimer’s disease. J Alzheimers Dis27, 163–176.
17.
HallA, MattilaJ, KoikkalainenJ, LotjonenJ, WolzR, ScheltensP, FrisoniG, TsolakiM, NobiliF, Freund-LeviY, MinthonL, FrolichL, HampelH, VisserPJ, SoininenH (2015) Predicting progression from cognitive impairment to Alzheimer’s disease with the Disease State Index. Curr Alzheimer Res12, 69–79.
18.
van der FlierWM, PijnenburgYA, PrinsN, LemstraAW, BouwmanFH, TeunissenCE, van BerckelBN, StamCJ, BarkhofF, VisserPJ, vanEE, ScheltensP (2014) Optimizing patient care and research: The Amsterdam Dementia Cohort. J Alzheimers Dis41, 313–327.
19.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
20.
VerhageF (2015) Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenzeventig jaar [Intelligence and Age: Study with Dutch people aged 12 to 77], Van Gorcum, Assen.
21.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCRJr, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
22.
ScheltensP, LaunerLJ, BarkhofF, WeinsteinHC, van GoolWA (1995) Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. J Neurol242, 557–560.
23.
PasquierF, LeysD, WeertsJG, Mounier-VehierF, BarkhofF, ScheltensP (1996) Inter- and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol36, 268–272.
24.
FazekasF, ChawlukJB, AlaviA, HurtigHI, ZimmermanRA (1987) MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR Am J Roentgenol149, 351–356.
25.
Munoz-RuizMA, HartikainenP, HallA, MattilaJ, KoikkalainenJ, HerukkaSK, JulkunenV, VanninenR, LiuY, LotjonenJ, SoininenH (2013) Disease state fingerprint in frontotemporal degeneration with reference to Alzheimer’s disease and mild cognitive impairment. J Alzheimers Dis35, 727–739.
26.
van de PolLA, ScheltensP (2014) Medial temporal lobe atrophy scores translated to clinical practice: Editorial comment on ‘influence of age, disease onset and ApoE4 on visual medial temporal lobe atrophy cut-offs’. J Intern Med275, 331–333.
27.
MulderC, VerweyNA, van der FlierWM, BouwmanFH, KokA, van ElkEJ, ScheltensP, BlankensteinMA (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem56, 248–253.
28.
DuitsFH, TeunissenCE, BouwmanFH, VisserPJ, MattssonN, ZetterbergH, BlennowK, HanssonO, MinthonL, AndreasenN, MarcussonJ, WallinA, RikkertMO, TsolakiM, ParnettiL, HerukkaSK, HampelH, De LeonMJ, SchroderJ, AarslandD, BlankensteinMA, ScheltensP, van der FlierWM (2014) The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?. Alzheimers Dement10, 713–723.e2.
29.
VosSJ, VerheyF, FrolichL, KornhuberJ, WiltfangJ, MaierW, PetersO, RutherE, NobiliF, MorbelliS, FrisoniGB, DrzezgaA, DidicM, van BerckelBN, SimmonsA, SoininenH, KloszewskaI, MecocciP, TsolakiM, VellasB, LovestoneS, MuscioC, HerukkaSK, SalmonE, BastinC, WallinA, NordlundA, deMA, SilvaD, SantanaI, LemosR, EngelborghsS, Van der MusseleS, Freund-LeviY, WallinAK, HampelH, van der FlierW, ScheltensP, VisserPJ (2015) Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage. Brain138(Pt 5), 1327–1338.
30.
YoudenWJ (1950) Index for rating diagnostic tests. Cancer3, 32–35.
31.
WeinerMW, VeitchDP, AisenPS, BeckettLA, CairnsNJ, GreenRC, HarveyD, JackCR, JagustW, LiuE, MorrisJC, PetersenRC, SaykinAJ, SchmidtME, ShawL, ShenL, SiuciakJA, SoaresH, TogaAW, TrojanowskiJQ (2013) The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement9, e111–e194.
32.
HallA, Munoz-RuizM, MattilaJ, KoikkalainenJ, TsolakiM, MecocciP, KloszewskaI, VellasB, LovestoneS, VisserPJ, LotjonenJ, SoininenH (2015) Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer’s disease. J Alzheimers Dis44, 79–92.
33.
Munoz-RuizMA, HallA, MattilaJ, KoikkalainenJ, HerukkaSK, VanninenR, LiuY, LotjonenJ, SoininenH (2014) Comparing predictors of conversion to Alzheimer’s disease using the disease state index. Neurodegener Dis13, 200–202.
34.
PalmqvistS, HertzeJ, MinthonL, WattmoC, ZetterbergH, BlennowK, LondosE, HanssonO (2012) Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer’s disease in mild cognitive impairment: Six-year follow-up study. PLoS One7, e38639.
35.
LandauSM, HarveyD, MadisonCM, ReimanEM, FosterNL, AisenPS, PetersenRC, ShawLM, TrojanowskiJQ, JackCRJr, WeinerMW, JagustWJ (2010) Comparing predictors of conversion and decline in mild cognitive impairment. Neurology75, 230–238.
36.
GainottiG, QuarantaD, VitaMG, MarraC (2014) Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer’s disease. J Alzheimers Dis38, 481–495.
37.
VosS, van RI, BurnsL, KnolD, ScheltensP, SoininenH, WahlundLO, HampelH, TsolakiM, MinthonL, HandelsR, L’ItalienG, van der FlierW, AaltenP, TeunissenC, BarkhofF, BlennowK, WolzR, RueckertD, VerheyF, VisserPJ (2012) Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging33, 2272–2281.
38.
VisserPJ, VerheyF, KnolDL, ScheltensP, WahlundLO, Freund-LeviY, TsolakiM, MinthonL, WallinAK, HampelH, BurgerK, PirttilaT, SoininenH, RikkertMO, VerbeekMM, SpiruL, BlennowK (2009) Prevalence and prognostic value of CSF markers of Alzheimer’s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol8, 619–627.
39.
PrestiaA, CaroliA, WadeSK, van der FlierWM, OssenkoppeleR, VanBB, BarkhofF, TeunissenCE, WallA, CarterSF, SchollM, ChooIH, NordbergA, ScheltensP, FrisoniGB (2015) Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. Alzheimers Dement11, 1191–1201.
40.
GuoLH, AlexopoulosP, EiseleT, WagenpfeilS, KurzA, PerneczkyR (2013) The National Institute on Aging-Alzheimer’s Association research criteria for mild cognitive impairment due to Alzheimer’s disease: Predicting the outcome. Eur Arch Psychiatry Clin Neurosci263, 325–333.
